Core Insights - The Hong Kong Traditional Chinese Medicine (TCM) stocks showed strong performance, with China Traditional Chinese Medicine rising over 8% initially before settling at a 2.9% increase, while other stocks like Wei Yuan Tang and Tong Ren Tang Guo Yao also saw gains [1][2] Industry Developments - The Ministry of Industry and Information Technology, along with eight other departments, issued the "Implementation Plan for High-Quality Development of the TCM Industry (2026-2030)" [1] - By 2030, a collaborative development system for the entire TCM industry chain is expected to be initially formed, with enhanced stable supply capabilities for key TCM raw materials and significant improvements in digitalization and greening levels [1] - The plan emphasizes the use of artificial intelligence and big data to create knowledge graphs for classic formulas and experiences from renowned TCM practitioners [1] Policy Implications - Analysts view this plan as a systemic, long-term policy benefit for TCM stocks, marking a shift from "extensive growth" to "quality and value-driven" development [1] - The plan serves as a "general program" for the development of the TCM industry over the next five years, focusing on raising industry standards, encouraging innovation, and driving a profound supply-side reform [1]

Group 1 - The core viewpoint of the news is that the Chinese traditional medicine sector is experiencing a strong market response following the release of a new development plan by the Ministry of Industry and Information Technology and seven other departments, which aims to enhance the quality and innovation of the industry by 2030 [1] - The plan outlines that by 2030, a collaborative development system for the entire traditional Chinese medicine (TCM) industry chain will be initially formed, with a focus on stable supply of key TCM raw materials and significant improvements in digitalization and greening levels [1] - Analysts suggest that this plan represents a systematic and long-term policy benefit for TCM stocks, marking a shift from "extensive growth" to "quality and value-driven" growth, serving as a guiding framework for the development of the TCM industry over the next five years [1] Group 2 - The stock performance of TCM companies shows a positive trend, with China Traditional Chinese Medicine rising over 8% at one point, currently up by 2.9%, and other companies like Yuyuan Tang and Tong Ren Tang also experiencing gains [2] - Specific stock price changes include: Yuyuan Tang at 0.365 with a 5.80% increase, China Traditional Chinese Medicine at 2.130 with a 2.90% increase, and Fosen Pharmaceutical at 0.750 with a 1.35% increase [2] - Other companies such as Tong Ren Rong Guo Yao, Baiyun Mountain, Tong Ren Tang Technology, and Jilin Changlong Pharmaceutical also reported slight increases in their stock prices, indicating a broader positive sentiment in the TCM sector [2]

中药概念集体高开，消息面上，2026年2月5日，工业和信息化部等八部门联合发布《中药工业高质量发 展实施方案（2026—2030年）》，本文件是对2025年3月《国务院办公厅 关于提升中药质量促进中医药 产业高质量发展的意见》的分解执行。文件部署了六方面任务：原料提质稳供、协同创新攻关、制造能 力提升、民族药产业振兴、卓越企业培育。到2030年，争取推动一批中药创新药获批上市，新培育10个 中成药大品种。分批次挖掘具有突出临床价值的中成药潜力品种，培育一批新的中成药大单品。依托中 国消费名品名单等载体，有序打造中药名品方阵 中药ETF紧密跟踪中证中药指数，中证中药指数选取涉及中药生产与销售等业务的上市公司证券作为样 本，以反映中药概念类上市公司的整体表现。 数据显示，截至2026年1月30日，中证中药指数(930641)前十大权重股分别为云南白药、片仔癀、东阿 阿胶、同仁堂、吉林敖东、华润三九、白云山、以岭药业、众生药业、达仁堂，前十大权重股合计占比 55.13%。 中药ETF(159647)，场外联接(A：016891；C：016892；I：022881)。 机构认为：基药目录即将出台，院内中药大单品呼之欲 ...

智通财经获悉，2月5日，工信部等八部门联合印发《中药（核心股）工业高质量发展实施方案(2026— 2030年)》，从全产业链视角为中药工业未来五年发展划定"路线图"。《方案》围绕原料供应、创新能 力、制造水平等维度设定量化目标：到2030年培育60个高标准中药原料生产基地、建设5个中药工业守 正创新中心、新培育10个中成药大品种，推动一批医疗机构中药制剂转化为中药创新药，制修订10项中 药工业数智技术相关行业标准，发布20个数智化转型升级典型案例，建设20个智能工厂、培育10个绿色 工厂。 相关概念股： 中国中药（核心股）(00570)：中国中药汇集传统中药精髓，传承了自明代以来开创的"梁仲弘腊丸 馆"、"冯了性"、"同济堂"、"源吉林"等祖铺老号，拥有"冯了性"、"安宁"、"同济堂"3个中华老字 号，"仙灵"、"同济堂"、"仙灵骨葆"、"天江药业"、"德众"5个驰名商标。 同仁堂国药(03613)：同仁堂集团有望新增一家A股上市公司。嘉事堂近日公告称，2月2日，公司股东与 中国北京同仁堂(集团)有限责任公司签署股份转让协议，约定将光大实业、光大健康持有的公司股份以 14.6亿元转让给同仁堂集团。本次交易完成 ...

展望2026年， 国内中药材市场有望在政策引导、需求升级与产业转型的三重驱动下迎来好转。国家药 监局出台的《中药生产监督管理专门规定》将于2026年3月1日起正式实施，与此前已落地的《中药注册 管理专门规定》《中药标准管理专门规定》形成"三位一体"的监管闭环，进一步推动行业规范化、高质 量发展。 结构性分化将成为2026年中药材市场的核心特征。一方面，野生中药材资源枯竭的问题日益凸显，家种 品种价值攀升，北柴胡、关防风等品种供需缺口持续扩大，价格有望稳步上涨；另一方面，在健康消费 升级的背景下，药食同源品种需求呈现刚性增长态势，枸杞、黄芪等品种应用场景不断拓展，将带动原 料需求增加。 2月5日，工信部等八部门联合印发《中药工业高质量发展实施方案(2026—2030年)》，从全产业链视角 为中药工业未来五年发展划定"路线图"。《方案》围绕原料供应、创新能力、制造水平等维度设定量化 目标：到2030年培育60个高标准中药原料生产基地、建设5个中药工业守正创新中心、新培育10个中成 药大品种，推动一批医疗机构中药制剂转化为中药创新药，制修订10项中药工业数智技术相关行业标 准，发布20个数智化转型升级典型案例，建设 ...

智通财经APP获悉，2月5日，工信部等八部门联合印发《中药工业高质量发展实施方案(2026—2030 年)》，从全产业链视角为中药工业未来五年发展划定"路线图"。《方案》围绕原料供应、创新能力、 制造水平等维度设定量化目标：到2030年培育60个高标准中药原料生产基地、建设5个中药工业守正创 新中心、新培育10个中成药大品种，推动一批医疗机构中药制剂转化为中药创新药，制修订10项中药工 业数智技术相关行业标准，发布20个数智化转型升级典型案例，建设20个智能工厂、培育10个绿色工 厂。 《方案》还提到，在原料端，实施"提质稳供行动"，不仅要建设高标准生产基地，还将推广中药材趁鲜 切制工艺，解决产地初加工"小散乱"问题。创新环节，《方案》提出构建经典名方知识图谱、推动医疗 机构制剂转化，破解中药新药研发"周期长、成本高"的难题。在制造能力提升上，《方案》明确加快制 定全国中药饮片炮制规范、配方颗粒国家标准，同时推动智能工厂建设，实现从原料溯源到成品放行的 全流程数据监控。 光大证券医药表示，2026年中药行业的投资逻辑将从"成本修复"转向"价值成长"，政策红利的持续释放 与企业经营效率的提升，将推动行业盈利水平 ...

Group 1 - The core viewpoint of the news is that traditional Chinese medicine (TCM) stocks are experiencing an upward trend, with Da Ren Tang rising over 5%, which in turn boosts the performance of various TCM ETFs [1] - Da Ren Tang announced a cash dividend distribution of 2.45 yuan per share, totaling approximately 1.886 billion yuan, based on a total share capital of 770,094,356 shares [2] - The TCM ETFs closely track the CSI Traditional Chinese Medicine Index, with major weighted stocks including Yunnan Baiyao, Pian Zai Huang, Dong E E Jiao, Tong Ren Tang, and others [1][2] Group 2 - New regulations are reshaping the TCM landscape, with the implementation of the Drug Administration Law and specific regulations for TCM registration, emphasizing a review system that combines traditional theory, human experience, and clinical data [3] - Century Securities believes that the TCM industry is likely to undergo a reshuffle due to recent policies promoting compliance and innovation, favoring leading enterprises with a strong reserve of classic formulas [3] - Xiangcai Securities indicates that the TCM material market is expected to transition towards scale, standardization, and branding, following a period of chaotic expansion [4] Group 3 - Three main investment themes are identified: price governance, consumption recovery, and state-owned enterprise reform [5][6] - Price governance focuses on the impact of price reductions through centralized procurement and insurance negotiations, with a recommendation to pay attention to unique products and companies with strong R&D capabilities [5] - The consumption recovery theme highlights the potential for increased sales of consumer TCM products due to macroeconomic recovery and an aging population, benefiting companies with brand and product advantages [6]

数据显示，截至2026年1月30日，中证中药指数(930641)前十大权重股分别为云南白药、片仔癀、东阿 阿胶、同仁堂、吉林敖东、华润三九、白云山、以岭药业、众生药业、达仁堂，前十大权重股合计占比 55.13%。 中药ETF(159647)，场外联接(A：016891；C：016892；I：022881)。 截至2026年2月5日 10:09，中证中药指数(930641)上涨0.92%，成分股达仁堂上涨3.67%，方盛制药上涨 3.62%，片仔癀上涨3.23%，华润江中上涨2.03%，广誉远上涨1.90%。中药ETF(159647)上涨0.92%， 冲 击3连涨。最新价报0.99元。 中药ETF紧密跟踪中证中药指数，中证中药指数选取涉及中药生产与销售等业务的上市公司证券作为样 本，以反映中药概念类上市公司的整体表现。 消息面上，多地政策持续支持中药产业，浙江提出培育壮大 生物医药等新兴产业，此前河南提出，培 育3—5个年营业收入超过30亿元的中药企业 建设具有全国影响力的中药产业集群。 世纪证券指出，1月27日，《中华人民共和国药品管理法实施条例》正式公布，配合2023年公布的《中 药注册管理专门规定》，确立 ...

格隆汇2月4日丨根据联交所最新权益披露资料显示，2026年1月30日，白云山(00874.HK)获JPMorgan Chase & Co.以每股均价18.8482港元增持好仓36.06万 股，涉资约679.7万港元。 | 夜給電視 | 大股東/董事/最高行政人員名 作出披露的 買入 / 賣出或涉及的 每股的平均價 | | | | | | 持有樓益的股份數目 佔已發行的 有關事件的日期 | | --- | --- | --- | --- | --- | --- | --- | --- | | | | | 发优惠 | | | ( 語参照 班 語 | 有投票權股(日/月/年) | | | | | | | | 日常 | 分自分 | | | | | | | | | 96 | | CS20260204E00260 | JPMorgan Chase & Co. | 1101(L) | | 360,600(L) | HKD 18.8482 | 20,060,314(L) | 9.12(L)30/01/2026 | | | | | | | | 3,229,564(S) | 1.46(S) | | | | | | | | 4,9 ...

Group 1 - The core point of the article is that JPMorgan has increased its stake in Guangzhou Pharmaceutical Holdings (00874) by purchasing 360,600 shares at a price of HKD 18.8482 per share, totaling approximately HKD 6.7967 million [1] - After the purchase, JPMorgan's total shareholding in Guangzhou Pharmaceutical Holdings is approximately 20.0603 million shares, representing a holding percentage of 9.12% [1]